Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for mild cognitive impairment due to Alzheimer's disease
NL-OMON24630Phase 2Recruiting
- Sponsor
- ZonMw
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast in mild cognitive impairment due to Alzheimer's disease (3 arms), sponsored by ZonMw. Primary endpoint: Episodic memory by Verbal Learning Test. Started Jan 2021; status: recruiting.
02
Drugs
roflumilast
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON24630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24630.